Bio-Rad

The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents. 

The firm's topline performance for the full year was also higher than previous guidance provided by the company and analyst estimates.

A jury in Northern California has found that Sanford Wadler was wrongfully terminated and awarded him back pay and punitive damages.

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.

Systems will ship in early February and include droplet-based library prep and analytics functionalities.

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco, CA, Day Two

The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.

The firm reported revenues of $508.7 million, thanks largely to an 18 percent increase in sales from the company's life science segment. 

The deal gives Bio-Rad licensing rights to a PCR-based platform and an assay that improves diagnostic sensitivity and efficacy across four dengue serotypes.

Pages

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.